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S206 Oral Presentationswithout deletion 17p appear to also have shorter time to relapse,
more follow up is needed. Further investigation of risk stratification
of MCL patients according to cytogenetic subgroup is warranted.
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MAINTAINED HEMATOLOGIC AND ORGAN RESPONSES FOLLOWING RISK
ADAPTED STEM CELL TRANSPLANT (SCT) IN SYSTEMIC LIGHT-CHAIN
AMYLOIDOSIS (AL) USING BORTEZOMIB AND DEXAMETHASONE AS
CONSOLIDATION THERAPY
Landau, H.J.1, Hassoun, H.1, Rosenzweig, M.A.2, Bello, C.1, Hoover, E.1,
Riedel, E.1, Comenzo, R.L.3 1Memorial Sloan-Kettering Cancer Center,
New York, NY; 2City of Hope Cancer Center, Duarte, CA; 3TuftsMedical
Center, Boston, MA
Background:Risk-adaptedMELdosing has improved the safety but
may also compromise the efficacy of SCT for pts with AL.We report
results of a phase II trial using bortezomib and dexamethasone (BD)
as consolidation following risk-adapted SCT for pts with AL.
Methods:Newly diagnosed pts with AL involving # 2 organs were
assignedMEL 100, 140 or 200mg/m2 with SCT, based on age, renal
function and cardiac involvement. Response was assessed at 2-3, 12,
and 24 mos post-SCT. Pts with persistent clonal plasma cell disease
at 2-3 mos post-SCT received consolidation with BD for up to 6 cy-
cles. Organ response and overall survival (OS) were assessed at 12
and 24 mos post-SCT.
Results: 41 pts with kidney (71%), heart (46%), liver/GI (12%) and
peripheral nervous system (12%) disease were enrolled; 44% had 2
organ-involvement. One pt was ineligible; 1 is within 100 days of
SCT. Four pts with advanced cardiac AL died within 100 days of
SCT, resulting in 10% (4/40) TRM. With median follow-up 39
mos, OS at 12 mos post-SCT was 88%. In pts with heart involve-
ment OS was 74% and 58% at 12 and 24 mos respectively, versus
100% at both time points in those without cardiac AL (P 5 0003).
Increased BNP and troponin were associated with worse OS, HR
1.3 (P 5 0.0001) and HR 3.9 (P 5 0.0003), respectively. Post-
SCT, the hematologic RR was 54% with 28% pts achieving CR.
For persistent clonal disease, 65% (22/34) received BD. Among all
pts evaluable at 12 mos post-SCT, the hematologic RR was 96%
(26/27) with 67% CR; 1 pt progressed. At 24 mos post-SCT the
RR was 84% (16/19) including 50% who maintained CR; 3 more
pts progressed. Of pts who received BD, 89% had an improved he-
matologic response; all responded after 1 cycle. Organ responses
evolved over time and were seen in 56% and 88% of pts at 12 and
24 mos post-SCT, respectively. In pts with renal AL, 45% (9/20)
achieved an organ response at 12 mos which increased to 92% (12/
13) by 24 mos. No pt had worsening organ function.
Conclusions: In newly diagnosed AL pts, BD following risk-adapt-
ed SCT is effective for eradicating persistent clonal disease. Hema-
tologic responses are rapid resulting in high overall and
unprecedented CR rates. Organ function improves in the majority
of patients, over time. Cardiac disease is associated with inferior
OS and cardiac biomarkers are useful for assigning risk. Relapses oc-
cur after completion of therapy and a maintenance regimen follow-
ing post-SCT consolidation is worthy of further study.
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GEMCITABINE, BUSULFAN AND MELPHALAN (Gem/Bu/Mel) IS A NEW
HIGH-DOSE CHEMOTHERAPY (HDC) REGIMEN WITH HIGH ACTIVITY
IN REFRACTORY OR POOR-RISK RELAPSED NON-HODGKIN’S LYM-
PHOMA (NHL) PATIENTS RECEIVING AN AUTOLOGOUS STEM-CELL
TRANSPLANT (ASCT)
Nieto, Y.1, Jones, R.B.1, Popat, U.1, Andersson, B.1, Valdez, B.1,
Thall, P.2, Shpall, E.J.1, Chancoco, C.1, Alousi, A.1, Anderlini, P.1,
Hosing, C.1, Qazilbash, M.1, Bashir, Q.1, Kebriaei, P.1, Khoui, I.1,
Ciurea, S.1, Parmar, S.1, Rondon, G.1, Champlin, R.1 1UT MD Ander-
son Cancer Center, Houston, TX; 2UT MD Anderson Cancer Center,
Houston, TX
Background: BEAM is considered a standard HDC regimen for
ASCT for NHL. However, pts with primary refractory tumors (fail-
ure to achieve a CR to 1st-line treatment) or high-risk relapse have
poor outcomes after BEAM or similar regimens, underscoring the
need for more active HDC combinations.Methods:We developed a new HDC regimen combining gemcita-
bine (Gem) with busulfan (Bu) and melphalan (Mel) (Gem/Bu/Mel)
pursuing DNA damage repair inhibition. Gem was infused at a fixed
rate of 10 mg/m2/min (optimizing its intracellular activation) x 2
(days -8 and -3), immediately preceding the first doses of Bu and
Mel. Bu was given as 4 daily doses (d-8 to -5) targeting AUC
4,000/d. Mel was given at 60 mg/m2/d (d-3 and -2). Gem dose was
escalated by extending its infusion in sequential cohorts. Pts with
CD20+ tumors received rituximab at 375 mg/m2 (d+1 and +8).
This trial was open to pts with refractory lymphoid tumors. NHL
pts with primary refractory disease, CR1 \12 months or .1 re-
lapse/PD were eligible.
Results:GemMTDwas identified as an infusion length of 4.5 hours
(total dose 2,550 mg/m2/d), causing manageable mucositis and rash.
In this study we included 46 NHL pts: 30 B-LCL (16 primary
DLCL, 2 double-hit myc+/BCL2+ LCL, 4 transformed, 4 primary
mediastinal, 4 primary CNS), 3 Burkitt’s, 2 follicular, 11 T-NHL
(6 anaplastic, 2 PTCL, 2 NK/T, 1 angioimmunoblastic). Median
age 53 (26-66), median 3 (2-9) prior regimens (prior Gem in 6), prior
radiotherapy 10 pts. Primary refractory and poor-risk relapsed dis-
ease in 22 and 24 pts, respectively. Other prognostic features in-
cluded: 1) No. prior relapses: 1: N 5 17, .1: N 5 29; 2) IPI at
relapse/PD: 0-1: 7 pts, .1: 33 pts (.3: 8 pts), N/A: 6 pts; 3) high
LDH at relapse/PD: 13 pts; 4) PET negative at HDC: 23 pts,
PET positive: 23 pts (11 of these in PD at ASCT).
The CR and overall RR were: 1) B-LCL: 69% and 100%; T-
NHL: 66% and 66%; Burkitt’s and follicular: all pts had a CR. All
6 pts with prior gemcitabine (none of whom had responded to it)
had a CR toGem/Bu/Mel. At median follow-up of 16 (2-57)months,
the EFS and OS rates are: 1) B-LCL: 80% and 83%, respectively; 2)
T-NHL: both 73%; 3) Burkitt’s: all 3 pts relapsed at 3 months and
died; 4) Follicular: 1 pt alive in CR, 1 pt alive in relapse.
Conclusions: Our preliminary results in refractory or poor-risk re-
lapsed NHL suggest high activity of Gem/Bu/Mel, particularly in
the B-LCL and T-cell histologies. Disease-specific phase 2 trials
are warranted.
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COMPARISON OF GEMCITABINE, BUSULFAN ANDMELPHALAN (Gem/Bu/
Mel) WITH BEAM AND BUSULFAN/MELPHALAN (Bu/Mel) IN CONCUR-
RENT COHORTS OF REFRACTORY HODGKIN’S LYMPHOMA (HL)
PATIENTS RECEIVING AN AUTOLOGOUS STEM-CELL TRANSPLANT
Nieto, Y.1, Jones, R.B.1, Liu, P.2, Anderlini, P.1, Popat, U.1,
Andersson, B.1, Shpall, E.J.1, Alousi, A.1, Hosing, C.1, Kebriaei, P.1,
Qazilbash, M.1, Frazier, E.1, Chancoco, C.1, Bashir, Q.1, Ciurea, S.1,
Parmar, S.1, Champlin, R.1 1UTMDAnderson Cancer Center, Houston,
TX; 2UT MD Anderson Cancer Center, Houston, TX
Background: BEAM is considered a standard HDC regimen for pts
with Hodgkin’s lymphoma (HL) who are candidates for an ASCT.
However, pts with primary refractory tumors or high-risk relapse
have poor outcomes after BEAM, underscoring the need for more
active HDC combinations.
Methods:We have developed a new HDC regimen of gemcitabine
(Gem), busulfan (Bu) and melphalan (Mel) (Gem/Bu/Mel), exploit-
ing their synergy based on DNA damage repair inhibition. At its
MTD, Gem was infused at a fixed dose rate of 10 mg/m2/min (opti-
mizing its intracellular activation) over 4.5 hours (d-8 and -3) (total
dose 5,550 mg/m2), preceding the first doses of Bu or Mel. Bu was
given as 4 daily doses (d-8 to -5) targeting AUC 4,000/d x4. Mel
was given at 60 mg/m2/d x2 (d-3 and -2). We compared the subset
of refractory HL pts of this study with all other refractory HL pts
transplanted during the same period at our institution, who were el-
igible for this trial but either received BEAMoff protocol or were en-
rolled in a separate trial of Bu/Mel. All of them met $1 of the
following criteria: primary induction failure (PIF) (\CR to 1st line
chemotherapy), CR1\6 mo, or .1 relapse. Pts with relapsed and
non-refractory HL were excluded from this analysis.
Results:We analyzed 209 pts in these cohorts: 1) Gem/Bu/Mel (N
5 89) (Jan 07-June 11), median f/u: 16 (3-57)mo; 2) BEAM (N5 83)
(Jan 05-Aug 11), median f/u: 17 (2-56) mo; 3) Bu/Mel (N5 37) (Apr
05-Dec 07), median f/u: 36 (17-56) mo. The Gem/Bu/Mel cohort
had substantially higher % PIF, .1 relapses, bulky tumors (.5
cm) at relapse/PD, extranodal disease at relapse/PD, PET+ tumors
at HDC and PD at HDC.
Oral Presentations S207Table 1. Clinical features
Gem/Bu/Mel BEAM Bu/Mel P valueN 89 83 37Age, median (range) 32 (19-61) 36 (17-67) 36 (20-63) 0.7% PIF 64 46 32 0.002% CR1 <6 mo 81 73 86 0.2% prior xRT 27 30 30 0.9% relapse within prior xRT field 12 9 11 0.8% >1 relapses 43 26 22 0.02% bulky tumor at relapse 37 18 22 0.009% B symptoms at relapse 15 14 8 0.6% extranodal disease at relapse 51 30 32 0.01% PET+ at HDC 52 28 27 0.001% PD at HDC 26 6 3 <0.0001The overall and CR rates were: Gem/Bu/Mel: 93% and 81%;
BEAM: 93% and 66%; Bu/Mel: both 64%. Despite its worse prog-
nostic features Gem/Bu/Mel pts had improved EFS (63% v 42% v
38%, P 5 0.002) and OS (85% v 63% v 62%, P 5 0.02) compared
to BEAM or Bu/Mel. Gem/Bu/Mel was superior in both PET-and
PET+ subsets. Cox regressionmodels identified the use of a regimen
other than GemBuMel [risk ratio 2.1 (95% CI, 1.3-3.5), P5 0.002],
PET+ tumors at HDC [RR 1.9 (1.2-3.1), P 5 0.002] and .1 prior
relapse [RR 1.8 (1.1-2.9), P 5 0.01] as independent adverse predic-
tors of EFS.
Conclusions:Despite its markedly worse prognostic features, refrac-
tory HL pts treated with the novel regimen Gem/Bu/Mel show supe-
rior outcome than contemporaneous pts receiving BEAM or Bu/Mel.
A randomized trial of Gem/Bu/Mel vs BEAM is warranted.
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HIGHER MELPHALAN EXPOSURE IS ASSOCIATED WITH IMPROVED
OVERALL SURVIVAL FOR MYELOMA PATIENTS UNDERGOING AUTOLO-
GOUS TRANSPLANT
Shaw, P.J.1,2, Nath, C.E.1, Nivison-Smith, I.3, Joshua, D.E.4,2,
Kerridge, I.H.5,2, Presgrave, P.6, Tiley, C.R.7, Kwan, Y.L.8,
Trotman, J.8,2 1Children’s Hospital at Westmead, Sydney, NSW, Aus-
tralia; 2University of Sydney; 3St Vincent’s Hospital, Sydney; 4Royal
Prince Alfred Hospital, Sydney; 5Royal North Shore Hospital, Sydney;
6Wollongong Hospital,Wollongong; 7Gosford Hospital, Gosford; 8Concord
Hospital, Sydney
Introduction and Aims:High dose melphalan (HDM) followed by
autologous stem cell transplantation (ASCT) has a central role in the
treatment ofmyeloma.Wehave already shown that patients given the
same dose ofHDMare exposed to a 5 fold variation in total exposure,
as measured by area-under-the-concentration-versus-time curve
(AUC) (1). It may be possible to improve outcomes by modifying
the individual patient dose to optimize their exposure to melphalan.
The aimof this studywas to investigate if exposure toHDMwas a sig-
nificant determinant of outcome in myeloma patients.
Methods:This study included myeloma patients undergoing HDM
at six hematology centres, from 2004-2010. Melphalan concentra-
tions were measured in 6-11 plasma samples collected after a median
dose of 192mg/m2 (range: 136–450 mg). This data was used to de-
velop a population pharmacokinetic model for melphalan (1) and
to determine total exposure to melphalan (AUC) for each patient.
In this pharmacodynamic analysis, we report the relationship be-
tween exposure to various levels of melphalan and clinical outcome.
Transplant toxicities were recorded using the Common Toxicity
Criteria. Factors affecting transplant toxicity and disease outcomes
were analysed by Cox regression analysis.
Results: A total of 115 patients (66 males, 49 females) aged 35-73
years (median 58 years) were studied, with a median follow-up of
3.1 years. Myeloma type was IgG (n 5 72), IgA (n 5 26), biclonal
(n 5 1), Light chain only (n 5 14) and non-secretory (n 5 2). Mel-
phalan AUC ranged from 4.9- 24.6 mg/L.h, median 12.85 mg/L.h.
Risk factors for mucositis of$Grade 3 were higher melphalan expo-
sure (HR1.17, p5 0.03) and higher pre-transplant b2-microglobulin
(HR 4.39, p5 0.007). Patients with AUC above the median were as-
sociated with the following: (1) improved Time to Progression
(TTP), HR 0.56, p\0.02, (2) improved overall survival (OS) at
both 2 years (91% versus 78%) and 4 years (82% versus 55%), HR0.35, (p 5 0.006). Progression free survival was not statistically sig-
nificant, HR 0.64, (p 5 0.08).
Conclusions: Detailed pharmacokinetic data following administra-
tion of HDM confirms that high exposure is associated with more
mucositis, but an improved outcome, as measured by TTP and
OS.These results suggest targeting a higher AUC is warranted in pa-
tients receiving HDM.
(1) Nath CE et al. Br.J.Clin.Pharmacol. 2010; 69: 484 – 497.
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INCIDENCE OF CARDIAC ARRHYTHMIAS DURING AUTOLOGOUS PERIPH-
ERAL BLOOD STEM CELL TRANSPLANTATION
Singla, A.1, Hogan, W.H.2, Ansell, S.M.2, Buadi, F.K.2, Dingli, D.2,
Dispenzieri, A.2, Gastineau, D.A.2, Gertz, M.A.2, Hayman, S.R.2,
Inwards, D.J.2, Johnston, P.B.2, Lacy, M.Q.2, Litzow, M.R.2,
Micallef, I.N.2, Porrata, L.F.2, Kumar, S.K.2 1Creighton University
Medical Center, Omaha, NE; 2Mayo Clinic, Rochester, MN
Background: Arrhythmias, especially supraventricular arrhythmias
(SVA), often complicate autologous stem cell transplantation
(ASCT).While easily treatable, they result in prolongation of hospi-
tal stay and increased rate of intensive care admissions. We under-
took this study to determine the incidence and risk factors for
cardiac arrhythmias during ASCT.
Methods:We examined the medical records of 983 patients who un-
derwent ASCT for various hematological malignancies between Aug
2006 andDec 2010.The underlying disease included plasma cell disor-
ders in 573 (58%)patients and lymphomaor leukemia in the remaining.
Results: The median age was 58 years (range; 19-77); 603 (61%)
were male. Overall, 92 (9.4%) patients developed a SVA following
ASCT, at a median of 9 days post transplant (range; 0, 18). Atrial fi-
brillation was most common and was seen in 71 (7%) patients, fol-
lowed by atrial flutter, supraventricular tachycardia and multifocal
tachycardia in 12 (1%), 8 (1%) and 1 (\1%) patients respectively.
The rhythm had normalized in 81 (88%) patients at the time of dis-
missal post transplant, with a median duration of arrhythmia of\1
day (range; \1 to 17 days). We then examined various pre and
peri-transplant clinical and laboratory parameters to identify risk fac-
tors for SVA. In a univariate analysis, older age, presence of supraven-
tricular complexes or AV conduction delays on pre-transplant ECG,
presence of any valvular abnormality, increased atrial size, any prior
history of arrhythmia, or being on a beta blocker or an antiarrhythmic
agent, all increased the risk. In a multivariate analysis, only age. 63
years, presence of supraventricular complexes or AV conduction de-
lays on pre-transplant ECG, and history of any prior arrhythmia in-
creased the risk of arrhythmia during transplant. Among the patients
with age . 63 years, presence of supraventricular complexes or AV
conduction delays on pre-transplant ECG, and history of any prior
arrhythmia, 20%, 26% and 23% respectively developed an arrhyth-
mia compared to 4%, 8% and 8% among those without the risk fac-
tors, respectively (P\ 0.001 for all three comparisons).
Conclusions: Among patients undergoing ASCT, 9% develop sup-
raventricular arrhythmias. The risk is elevated among the older pa-
tients, those with a prior history of arrhythmias, and those with
AV conduction delay or premature supraventricular complexes on
ECG. Identification of patients at a higher risk may allow develop-
ment of specific interventions.ALLOGENEIC TRANSPLANTS15
B CELLS FROM PATIENTS WITH CHRONIC GVHD SIGNAL VIA THE AKT-
DRIVEN SURVIVAL AND METABOLIC FITNESS PATHWAY
Allen, J.L.1, Wooten, J.1, Fore, M.1, Bhuiya, N.S.2, Armistead, P.3,
Coghill, J.M.3, Gabriel, D.3, Roehrs, P.A.4, Sharf, A.5, Irons, R.N.5,
Hoffert, T.6, Richards, K.7, Shea, T.C.3, Baldwin, A.S.1, Serody, J.1,3,
Sarantopoulos, S.1,3 1University of North Carolina, Chapel Hill, NC;
2Cambridge Health Alliance, Boston, MA; 3UNC School of Medicine,
Chapel Hill, NC; 4UNC School of Medicine, Chapel Hill, NC; 5UNC
School of Medicine, Chapel Hill, NC; 6UNC School of Medicine, Chapel
Hill, NC; 7UNC School of Medicine, Chapel Hill, NC
Allogeneic hematopoietic stemcell transplant patients (HSCT)who
develop chronic GVHD (cGVHD) have delayed B cell reconstitution
